Regenxbio Inc (RGNX) Stock Price, Quote & News

Company Profile

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 552 8181

Website: www.regenxbio.com

Address:

9804 Medical Center Drive, Rockville, United States

maphere Jun. 4 at 8:35 PM

$RGNX From the round table discussion yesterday for rare disease, a letter from EveryLife Foundation: https://everylifefoundation.org/fda-rare-disease-roundtable-june-3-2026/ This brings political pressure on the FDA to: 1. Support for accelerated approval based on surrogate biomarkers 2. Support for external controls and real-world evidence 3. Pressure to accept smaller datasets in rare diseases

2 · Reply

Teillbou Jun. 3 at 4:56 PM

$RGNX where is that 100M from AbbVie it is taking too much time no? First patient must be dosed already

1 · Reply

Wolfman5960 Jun. 3 at 2:11 PM

$RGNX Here are the results from the Annual Shareholders meeting vote. Looks like everything passed except for the options exchange program for executive employees. The non-executive employees options exchange program passed so they'll be able to reset their options priced at or above $18 which is good. The executives will need to execute and get the stock price back up in order to be in the money on their options.

3 · Reply

rando321456 Jun. 3 at 9:26 AM

$RGNX It's still blowing my mind the market is ignoring the sea change in the FDA. For both 121 and 202 we have the patient advocacy groups behind us, I just don't see how both are not approved in some fashion over the next 18 months(assuming 202's safety holds up in the confirmatory)

0 · Reply

gsgofish Jun. 2 at 9:41 PM

$RGNX did numerous insiders recently purchase stock ?

0 · Reply

maphere Jun. 2 at 4:22 PM

$RGNX June 12th Regenxbio sponsoring 3-hour presentation on upcoming DR trial at 12-3:00 (thank you @rando321456 ) https://web.cvent.com/event/cf678d9e-77b7-4f1a-a762-6f92d99a0a6e/register?environment=P2 This is coordinated with a high-level ophthalmology conferce Clinical Trials at the Summit that has registration the same day starting at 3:00 at the Fontainebleau Las Vegas This Summit is headed up by Dr. Khanani who is a big-time Dr. invested in RGNX clinical trials. https://www.ctsretina.org/hotel-and-travel

0 · Reply

beachlife2103 Jun. 2 at 2:33 PM

$SGMO $QURE $SRPT $RGNX $RARE

0 · Reply

biotech Jun. 2 at 2:25 PM

$SGMO $QURE $SRPT $RGNX $RARE FDA Acting Head to Meet Closed-Door With Rare Disease Groups scheduled for Wednesday, Kyle Diamantas and other senior agency officials will meet with at least 10 rare disease groups for a private conversation about advancing treatments Diamantas has made it a #priority to meet with as many parties as possible, especially #rare disease groups https://news.bloomberglaw.com/health-law-and-business/fdas-acting-head-to-meet-closed-door-with-rare-disease-groups

1 · Reply

SQUEAKSBANDIT Jun. 2 at 2:12 PM

$RGNX that was an efficient way to take out 3 days gains in half an hour not really liking it but added some for anyone who might know does the $FULC news today at all read through to RGNX

1 · Reply

chivo12 Jun. 2 at 1:56 PM

$RGNX I think the results of annual shareholder meeting vote should get filed with SEC today or tomorrow. Will be interesting to see the results of the vote on executive option re-pricing. I am generally opposed to these re-pricing proposals, and with this one in particular thought the number of options forfeited was too low relative to the reduction in exercise price. But with that being said, assuming it passed, I would think that the executive option holders should be more supportive of being acquired.

0 · Reply

REGENXBIO Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 18, 2026, 4:05 PM EDT - 17 days ago

REGENXBIO to Participate in Upcoming Investor Conferences

2026-05-15T15:49:06.000Z - 20 days ago

Regenxbio price target lowered to $16 from $17 at Morgan Stanley

2026-05-15T10:40:05.000Z - 20 days ago

Regenxbio price target lowered to $14 from $25 at BofA

2026-05-15T09:10:09.000Z - 20 days ago

Regenxbio price target lowered to $12 from $37 at Barclays

May 14, 2026, 9:30 AM EDT - 21 days ago

REGENXBIO Earnings release: Q1 2026

May 14, 2026, 9:30 AM EDT - 21 days ago

REGENXBIO Quarterly report: Q1 2026

2026-05-14T13:02:06.000Z - 21 days ago

Regenxbio reports Q1 EPS ($1.72) vs. 12c last year

2026-05-14T12:54:52.000Z - 21 days ago

Regenxbio expects cash, equivalents to fund operations into early 2027

2026-05-14T12:31:15.000Z - 21 days ago

Regenxbio’s RGX-202 shows efficacy in Phase 3 Duchenne trial

May 14, 2026, 8:00 AM EDT - 21 days ago

REGENXBIO Transcript: Study result

May 14, 2026, 8:00 AM EDT - 21 days ago

REGENXBIO Press release: Study result

May 14, 2026, 8:00 AM EDT - 21 days ago

REGENXBIO Slides: Study result

May 14, 2026, 7:10 AM EDT - 21 days ago

REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights

May 14, 2026, 7:04 AM EDT - 21 days ago

Regenxbio's muscle disorder therapy meets main goal in late-stage study

May 14, 2026, 7:00 AM EDT - 21 days ago

REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202

May 7, 2026, 7:05 AM EDT - 4 weeks ago

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

May 6, 2026, 7:05 AM EDT - 4 weeks ago

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

Apr 14, 2026, 8:00 AM EDT - 7 weeks ago

REGENXBIO Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 7 weeks ago

REGENXBIO Proxy statement: Proxy filing

Apr 3, 2026, 8:00 AM EDT - 2 months ago

REGENXBIO Proxy statement: Proxy filing

Mar 26, 2026, 9:00 AM EDT - 2 months ago

SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD

2026-03-24T15:47:52.000Z - 2 months ago

Shareholders Sue RGNX Over Gene Therapy Study Claims

Mar 11, 2026, 12:00 PM EDT - 3 months ago

Regenxbio's Duchenne gene therapy shows improved muscle function in trial

2026-03-11T15:56:10.000Z - 3 months ago

Regenxbio reports interim data from Phase I/II AFFINITY DUCHENNE trial

Mar 11, 2026, 11:45 AM EDT - 3 months ago

REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

Mar 10, 2026, 1:30 PM EDT - 3 months ago

REGENXBIO Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 9, 2026, 9:20 AM EDT - 3 months ago

REGENXBIO Transcript: Leerink Global Healthcare Conference 2026

2026-03-09T10:15:30.000Z - 3 months ago

Regenxbio price target lowered to $30 from $32 at H.C. Wainwright

Mar 6, 2026, 11:33 AM EST - 3 months ago

FDA reversals leave investors worrying about the fates of other experimental drugs

DNLI MRNA WVE

2026-03-05T20:15:32.000Z - 3 months ago

Regenxbio price target lowered to $17 from $18 at Morgan Stanley

Mar 5, 2026, 2:25 PM EST - 3 months ago

RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST

Mar 5, 2026, 8:00 AM EST - 3 months ago

REGENXBIO Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:00 AM EST - 3 months ago

REGENXBIO Annual report: Q4 2025

Mar 5, 2026, 8:00 AM EST - 3 months ago

REGENXBIO Earnings release: Q4 2025

Mar 5, 2026, 7:05 AM EST - 3 months ago

REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Mar 4, 2026, 7:05 AM EST - 3 months ago

REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 2, 2026, 5:58 PM EST - 3 months ago

REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses

Feb 25, 2026, 7:05 AM EST - 3 months ago

REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Feb 9, 2026, 4:13 PM EST - 4 months ago

US FDA declines to approve Regenxbio's rare disease drug

Feb 9, 2026, 4:05 PM EST - 4 months ago

REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II

Jan 29, 2026, 6:06 PM EST - 4 months ago

Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action

Jan 28, 2026, 7:46 AM EST - 4 months ago

US FDA places clinical hold on Regenxbio's gene therapy trials

Jan 28, 2026, 7:30 AM EST - 4 months ago

REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs

Jan 14, 2026, 1:30 PM EST - 5 months ago

REGENXBIO Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 3:00 PM EST - 5 months ago

REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program

Jan 10, 2026, 7:00 AM EST - 5 months ago

REGENXBIO Slides: Corporate presentation

Dec 18, 2025, 7:05 AM EST - 6 months ago

REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 2, 2025, 8:30 AM EST - 6 months ago

REGENXBIO Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 7:00 AM EST - 6 months ago

REGENXBIO Registration statement: Registration Filing

Nov 25, 2025, 7:05 AM EST - 6 months ago

REGENXBIO to Participate in Upcoming Investor Conference

Nov 11, 2025, 1:20 PM EST - 7 months ago

REGENXBIO Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 7 months ago

REGENXBIO Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 8:00 AM EST - 7 months ago

REGENXBIO Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:00 AM EST - 7 months ago

REGENXBIO Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 7 months ago

REGENXBIO Earnings release: Q3 2025

Nov 6, 2025, 7:05 AM EST - 7 months ago

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

Oct 30, 2025, 7:05 AM EDT - 7 months ago

REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program

Oct 29, 2025, 7:05 AM EDT - 7 months ago

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

Oct 9, 2025, 7:05 AM EDT - 8 months ago

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

Oct 6, 2025, 7:05 AM EDT - 8 months ago

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

Sep 29, 2025, 7:05 AM EDT - 8 months ago

REGENXBIO Announces Presentation at the World Muscle Society

Sep 8, 2025, 11:30 AM EDT - 9 months ago

REGENXBIO Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 5, 2025, 7:05 AM EDT - 9 months ago

REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II

Aug 18, 2025, 5:00 PM EDT - 10 months ago

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

Aug 7, 2025, 8:00 AM EDT - 10 months ago

REGENXBIO Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 10 months ago

REGENXBIO Quarterly report: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 10 months ago

REGENXBIO Earnings release: Q2 2025

Aug 7, 2025, 7:05 AM EDT - 10 months ago

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

Aug 7, 2025, 7:00 AM EDT - 10 months ago

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

Jul 31, 2025, 7:05 AM EDT - 11 months ago

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

Jul 10, 2025, 11:54 AM EDT - 11 months ago

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

maphere Jun. 4 at 8:35 PM

2 · Reply

Teillbou Jun. 3 at 4:56 PM

$RGNX where is that 100M from AbbVie it is taking too much time no? First patient must be dosed already

1 · Reply

Wolfman5960 Jun. 3 at 2:11 PM

3 · Reply

rando321456 Jun. 3 at 9:26 AM

0 · Reply

gsgofish Jun. 2 at 9:41 PM

$RGNX did numerous insiders recently purchase stock ?

0 · Reply

maphere Jun. 2 at 4:22 PM

0 · Reply

beachlife2103 Jun. 2 at 2:33 PM

$SGMO $QURE $SRPT $RGNX $RARE

0 · Reply

biotech Jun. 2 at 2:25 PM

1 · Reply

SQUEAKSBANDIT Jun. 2 at 2:12 PM

$RGNX that was an efficient way to take out 3 days gains in half an hour not really liking it but added some for anyone who might know does the $FULC news today at all read through to RGNX

1 · Reply

chivo12 Jun. 2 at 1:56 PM

0 · Reply

Wolfman5960 Jun. 1 at 8:42 PM

$RGNX Interesting article I just saw saying that Kyle Diamantas will be having a closed door roundtable meeting with around a dozen rare disease groups this Wednesday: https://news.bloomberglaw.com/pharma-and-life-sciences/fdas-acting-head-to-meet-closed-door-with-rare-disease-groups Hopefully the rare disease groups like NORD can put pressure on the FDA to show more flexibility for rare diseases. We'll see but its a good sign that the acting FDA commissioner is taking time to meet with the rare disease groups. Hopefully it translates into actual action from them.

0 · Reply

maphere Jun. 1 at 4:27 PM

$RGNX The upcoming PR to release the $100,000,000 may also state: "global development progressing rapidly" "expanded collaboration on new molecules" "accelerated enrollment plans" "physician enthusiasm is high" Additional funding from ABBV for the new capsid via SCS for GA would be a huge confidence builder

1 · Reply

SQUEAKSBANDIT Jun. 1 at 3:43 PM

$RGNX took some earlier holding up well so far even in the face of $XBI dump $RGNX wants to go higher

0 · Reply

Ml55totoag May. 31 at 3:49 AM

$RGNX The 314 pioneers exciting to watch in utube.

0 · Reply

rando321456 May. 30 at 1:10 AM

$RGNX Putting this out there for anyone to push back on(and may be abit of a repetition of a prior thought) but in NPDR afaik no one is even planning phase 2 trials in the other gene therapy candidates that are in pivotals for wet AMD and going into DME. I figure it would take in the best case 6 months to setup a phase 2, 18 months to recruit the trial and get data and 12 months to get FDA alignment on the pivotal and setup the trial. So Regenx should atleast be 3 years ahead of any followers currently. Realistically it's more like 5 years accounting for disinterest in the indication and the lack of resources in the other late stage trials. If Regenx gets through the pivotals without anyone trying to be a follower it'll be about 6-7 years.

3 · Reply

Wolfman5960 May. 29 at 1:07 PM

$RGNX Good sign this morning from the FDA on being more flexible. Looks like Replimune will get a third shot at a review. https://www.wsj.com/health/pharma/replimune-gets-third-try-at-fda-approval-after-makary-departure-831e07ee

2 · Reply

BluntForceOptions May. 29 at 12:02 PM

$RGNX has acted well so far. Added exposure by selling the June 18, 6 puts last week, before the pop, with the breakeven around $5.55. It’s been a solid setup and price action is doing exactly what we want to see. If the tape gives us any weakness, I'll be looking to scale into more of the common equity.

0 · Reply

DarkOrb May. 29 at 5:49 AM

$RGNX Here's a link to CureDuchenne's Regenxbio Webinar for 202 from May 19. Not sure if this has been shared here yet. https://www.youtube.com/watch?v=4dgl64VAZwE

2 · Reply

CooperHandy May. 28 at 5:40 PM

$RGNX

2 · Reply

maphere May. 28 at 2:46 PM

$RGNX Stifel: Buy Rating: PT $42 https://m.uk.investing.com/news/stock-market-news/stifel-reiterates-buy-rating-on-regenxbio-stock-ahead-of-trial-data-93CH-4700799?ampMode=1

0 · Reply

PB09 May. 27 at 9:23 PM

$RGNX Exited my position today for 10k profit may be left early but will get back in if it goes under $6 again

1 · Reply

explover May. 27 at 6:20 PM

$RGNX looks like this could easily be taken out by AbbVie or another BP very cheaply at a 150-200% premium or something, lots of patent-protected value in specific assets and the platform, clean cap table, shelf ready, tight/uncertain on cash without dilution

4 · Reply

Market Cap	345.86M
Revenue (ttm)	170.44M
Net Income (ttm)	-193.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-113.75%
Debt to Equity Ratio	0.00

Volume	1,250,900
Avg Vol	1,242,436
Day's Range	N/A - N/A
Shares Out	51.70M
Stochastic %K	65%
Beta	1.04
Analysts	Strong Sell
Price Target	$26.00